US FDA approves Takeda, Protagonist's drug for rare blood cancer
PTGX•FDA approves Takeda and Protagonist drug for rare blood cancer
The U.S. Food and Drug Administration has approved a first-of-its-kind drug from Takeda Pharmaceutical and Protagonist Therapeutics to treat a rare blood cancer, the health regulator said on Friday.
